Cris Neckar
Investing Profile
Two Bear Capital thesis
Abilita Therapeutics Abilita Therapeutics enables discovery of novel therapeutics for previously undruggable membrane protein targets. Abilita Therapeutics enables discovery of novel therapeutics for previously undruggable membrane protein targets. About the company Abilita Therapeutics on LinkedIn Abilita Therapeutics website Abilita Therapeutics is a biotech company specializing in discovering and developing therapies for the most challenging membrane proteins, including GPCRs, ion channels and transporters. Despite their high significance, hundreds of such drug targets remain untapped. Abil
Sector and stage focus
- general: Investors who were founders, Investors who invested in diverse founders, Investors who invested in female founders, New York City, DefenseTech, Los Angeles / Southern California, Washington, D.C., DefenseTech, San Francisco Bay Area, DefenseTech, DefenseTech
- Seed: Security, Impact, DeepTech, Supply Chain Tech, SaaS, Enterprise, AI, Cybersecurity, Enterprise Infrastructure
- Series A: Enterprise, DeepTech, Impact, Security, Cybersecurity, AI, SaaS, Enterprise Infrastructure, Supply Chain Tech
Recent investments by Cris Neckar
Cris Neckar has 4 named past investments in the public record. The most recent:
| Company | Stage | Date | Round size |
|---|---|---|---|
| Revenium | Seed | Nov 2025 | $14M |
| Binarly | Seed | Mar 2024 | $11M |
| Dymium | Seed | Mar 2024 | $7M |
| QuSecure | Series A | Feb 2025 | $28M |
Frequent co-investors
Cris Neckar has co-invested with: Kevin Moore.
Is Cris Neckar a fit for your round?
Upload your pitch deck and see whether Cris Neckar appears in your top 20 matches.
Find investors for your deck